View in EDS HTML Full Text PDF Full Text

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.

Saved in:
Bibliographic Details
Title: Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.
Authors: George DJ; Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA daniel.george@duke.edu., Hessel C; Exelixis, Inc., Alameda, California, USA., Halabi S; Alliance Statistics and Data Center, and Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA., Michaelson MD; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Hahn O; Alliance Protocol Operations Office, Chicago, Illinois, USA., Walsh M; Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA., Picus J; Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA., Small EJ; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA., Dakhil S; University of Kansas - Wichita, Wichita, Kansas, USA., Feldman DR; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Mangeshkar M; Exelixis, Inc., Alameda, California, USA., Scheffold C; Exelixis, Inc., Alameda, California, USA., Morris MJ; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Choueiri TK; Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.
Source: The oncologist [Oncologist] 2019 Nov; Vol. 24 (11), pp. 1497-1501. Date of Electronic Publication: 2019 Aug 09.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 31399500
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22George+DJ%22">George DJ</searchLink>; Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA daniel.george@duke.edu.<br /><searchLink fieldCode="AU" term="%22Hessel+C%22">Hessel C</searchLink>; Exelixis, Inc., Alameda, California, USA.<br /><searchLink fieldCode="AU" term="%22Halabi+S%22">Halabi S</searchLink>; Alliance Statistics and Data Center, and Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Michaelson+MD%22">Michaelson MD</searchLink>; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Hahn+O%22">Hahn O</searchLink>; Alliance Protocol Operations Office, Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Walsh+M%22">Walsh M</searchLink>; Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Picus+J%22">Picus J</searchLink>; Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.<br /><searchLink fieldCode="AU" term="%22Small+EJ%22">Small EJ</searchLink>; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Dakhil+S%22">Dakhil S</searchLink>; University of Kansas - Wichita, Wichita, Kansas, USA.<br /><searchLink fieldCode="AU" term="%22Feldman+DR%22">Feldman DR</searchLink>; Memorial Sloan Kettering Cancer Center, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Mangeshkar+M%22">Mangeshkar M</searchLink>; Exelixis, Inc., Alameda, California, USA.<br /><searchLink fieldCode="AU" term="%22Scheffold+C%22">Scheffold C</searchLink>; Exelixis, Inc., Alameda, California, USA.<br /><searchLink fieldCode="AU" term="%22Morris+MJ%22">Morris MJ</searchLink>; Memorial Sloan Kettering Cancer Center, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Choueiri+TK%22">Choueiri TK</searchLink>; Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229607837%22">The oncologist</searchLink> [Oncologist] 2019 Nov; Vol. 24 (11), pp. 1497-1501. <i>Date of Electronic Publication: </i>2019 Aug 09.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9607837 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-490X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210837159%22">10837159 </searchLink><i>NLM ISO Abbreviation: </i>Oncologist <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=31399500
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1634/theoncologist.2019-0316
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1497
    Titles:
      – TitleFull: Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: George DJ
      – PersonEntity:
          Name:
            NameFull: Hessel C
      – PersonEntity:
          Name:
            NameFull: Halabi S
      – PersonEntity:
          Name:
            NameFull: Michaelson MD
      – PersonEntity:
          Name:
            NameFull: Hahn O
      – PersonEntity:
          Name:
            NameFull: Walsh M
      – PersonEntity:
          Name:
            NameFull: Picus J
      – PersonEntity:
          Name:
            NameFull: Small EJ
      – PersonEntity:
          Name:
            NameFull: Dakhil S
      – PersonEntity:
          Name:
            NameFull: Feldman DR
      – PersonEntity:
          Name:
            NameFull: Mangeshkar M
      – PersonEntity:
          Name:
            NameFull: Scheffold C
      – PersonEntity:
          Name:
            NameFull: Morris MJ
      – PersonEntity:
          Name:
            NameFull: Choueiri TK
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2019 Nov
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-electronic
              Value: 1549-490X
          Numbering:
            – Type: volume
              Value: 24
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: The oncologist
              Type: main
ResultId 1